Download PDF
Thromb Haemost 2000; 83(04): 540-544
DOI: 10.1055/s-0037-1613859
Commentary
Schattauer GmbH

Use of the PFA-100™ Apparatus to Assess Platelet Function in Patients Undergoing PTCA during and after Infusion of cE3 Fab in the Presence of other Antiplatelet Agents

Nathalie Hézard
1   From the Laboratoire Central d’Hématologie
,
Damien Metz
2   Service de Cardiologie, CHU Robert Debré, Reims, France
,
Pierre Nazeyrollas
2   Service de Cardiologie, CHU Robert Debré, Reims, France
,
Chantal Droulle
1   From the Laboratoire Central d’Hématologie
,
Jacques Elaerts
2   Service de Cardiologie, CHU Robert Debré, Reims, France
,
Gérard Potron
1   From the Laboratoire Central d’Hématologie
,
Philippe Nguyen
1   From the Laboratoire Central d’Hématologie
› Author Affiliations
Further Information

Publication History

Received 14 September 1999

Accepted after resubmission 13 December 1999

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

Summary

The PFA-100™ (Dade) is a new functional whole blood analyzer, the accuracy and reliability of which have been evaluated in von Willebrand disease and during acetyl salicylate acid therapy. This new test has the advantages of rapidity and simplicity. It may be useful to monitor new antiplatelet agents, such as GPIIb/IIIa receptor antagonists. The objective of this study was to assess the PFA-100™ in comparison with aggregometry and with the percentage of blockaded receptors GPIIb/IIIa during and after c7E3 Fab infusion in fifteen patients undergoing PTCA. Our results showed a change of closure time values from normal to abnormal within a small margin of flow cytometric values (60–75% of blockaded receptors), and moreover a variable platelet response to long-term low dose aspirin treatment in agreement with aggregometry. No influence with heparin was observed. In conclusion, this study shows that PFA-100™ may be helpful in the decision making for additional antiaggregant therapy before PTCA or in monitoring long-term GPIIb/IIIa receptor antagonist treatment.

Keywords

c7E3 Fab - acetyl salicylate acid - PFA-100™ - platelet - monitoring
 

  • References

  • 1 Smith JW, Steinhubl SR, Lincoff M, Coleman JC, Lee TT, Hillman RS, Coller BS. Rapid platelet-function assay. An automated and quantitative cartridge-based method. Circulation 1999; 99: 620-25.
    CrossrefPubMedGoogle Scholar
  • 2 Bernardi MM, Califf RM, Kleiman NS, Ellis SG, Topol EJ. for the TAMI Study Group. Prolonged bleeding times do not predict hemorrhagic events in patients receiving c7E3 GPIIb/IIIa platelet antibody. Circulation 1992; 86: I-260 Abstract.
    PubMedGoogle Scholar
  • 3 Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, Cove CS, DeFranco AC, Ellis SG, Moliterno DJ, Raymond RE, Sutton JM, Topol EJ. First chronic platelet GPIIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of Xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997; 96: 76-81.
    CrossrefPubMedGoogle Scholar
  • 4 Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E. for the TIMI 12 Investigators. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, Sibrafiban, in patients after an acute coronary syndrome. Results of the TIMI 12 trial. Circulation 1998; 97: 340-9.
    CrossrefPubMedGoogle Scholar
  • 5 Kereiakes DJ, Kleiman NS, Ferguson JJ, Masud ARZ, Broderick TM, Abbotsmith CW, Runyon JP, Anderson LC, Anders RJ, Dreiling RJ, Hantsbarger GL, Bryzinski B, Toplol EJ. for the Oral Glycoprotein IIb/IIIa Receptor Blockade to Inhibit Thrombosis (ORBIT) Trial Investigators. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral Xemilofiban. Circulation 1998; 98: 1268-78.
    CrossrefPubMedGoogle Scholar
  • 6 Simoons ML, de Boer MJ, van den Brand MJBM, van Miltenburg AJM, Hoorntje JCA, Heyndrickx GR, van der Wieken LR, De Bono D, Rutsch W, Schaible TF, Weisman HF, Klootwijk P, Nijssen KM, Stibbe J, de Feyter PJ. and the European Cooperative Study Group. Randomized trial of GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603.
    CrossrefPubMedGoogle Scholar
  • 7 Kleiman NS, Ohman EM, Califf RM, George BS, Kereikaes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993; 22: 381-9.
    CrossrefPubMedGoogle Scholar
  • 8 Wagner C, Mace K, Mascelli MA, DeRita R, Lance E, Weisman H, Ghrayeb J, Jordan R. Pharmacodynamics of ReoPro (c7E3 Fab): free plasma levels determine clinical efficacy. Thromb Haemost 1997; S: 7-8 Abstract.
    PubMedGoogle Scholar
  • 9 Riederer MA, Steiner B. The extend of platelet aggregation is dependent on the free GPIIb/IIIa concentration and not the % receptor occupancy. Thromb Haemost 1997; S: 6-7 Abstract.
    PubMedGoogle Scholar
  • 10 Anderson DR, Zayed E, Embree J, Theroux P, Steiner B. Flow cytometry as a quantitative measure of the antiplatelet activity of a glycoprotein IIb/IIIa inhibitor. Blood 1997; 86: 893 Abstract.
    PubMedGoogle Scholar
  • 11 Liu CZ, Hur BT, Huang TF. Measurement of glycoprotein IIb/IIIa blockade by cytometry with fluorescein isothiocyanate-conjugated crotavirin, a member of disintegrins. Thromb Haemost 1996; 76: 585-91.
    PubMedGoogle Scholar
  • 12 Hézard N, Metz D, Nazeyrollas P, Nguyen P, Simon G, Daliphard S, Elaerts J, Potron G. Free and total platelet glycoprotein IIb/IIIa measurement in whole blood by quantitative flow cytometry during and after infusion of c7E3 Fab in patients undergoing PTCA. Thromb Haemost 1999; 81: 869-73.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Mascelli MA, Worley S, Veriabo NJ, Lance HT, Mack S, Schaible T, Weisman HF, Jordan RE. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GPIIb/IIIa therapy. Circulation 1997; 96: 3860-66.
    CrossrefPubMedGoogle Scholar
  • 14 Coller BS, Lang D, Scudder LE. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 1997; 95: 860-7.
    CrossrefPubMedGoogle Scholar
  • 15 Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ. PFA-100™ System: a new method for assessment of platelet dysfunction. Sem Thromb Haemost 1998; 24: 195-202.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Kundu SK, Heilmann EJ, Sio R, Garcia C, Ostgaard RA. Characterization of an in vitro platelet function analyzer, PFA-100™. Clin Appl Thromb Haemost 1996; 02: 241-9.
    CrossrefPubMedGoogle Scholar
  • 17 Fressinaud E, Veyradier A, Truchaud F, Martin I, Boyer-Neumann C, Trossaert M, Meyer D. Screening for von Willebrand disease with a new analyser using high shear stress: a study of 60 cases. Blood 1998; 91: 1325-31.
    PubMedGoogle Scholar
  • 18 Cattaneo M, Federici AB, Lecchi A, Agati B, Lombardi R, Stabile F, Bucciarelli P. Evaluation of the PFA-100® system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Throm Haemost 1999; 82: 35-9.
    PubMedGoogle Scholar
  • 19 Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyser – PFA-100™. Sem Thromb Haemost 1995; 21: 106-12.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 294: 927-9.
    PubMedGoogle Scholar
  • 21 Böhner J, von Pape KW, Wiebersinsky W, Alan E, Wuttke M, Dölp R. Serial assessment of platelet function following a single 300 mg dose of acetylsalicylic acid. Ann Haematol 1997; 74: 136 Abstract.
    PubMedGoogle Scholar
  • 22 Borries M, Söhngen D, Englisch C, Schoebel FC, Stein D, Stiegler H, Boogen C, Strauer BE, Leschke M. Measurement of the effect of aspirin and ticlopidin on platelet function with a simple in vitro bleeding test. Ann Haematol 1997; 74: 137 Abstract.
    PubMedGoogle Scholar
  • 23 Kottke-Marchant K, Powers JB, Brooks L, Kundu S, Christie DJ. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the Platelet Function Analyzer (PFA-100®). Clin Appl Throm Haemost 1999; 05: 122-30.
    PubMedGoogle Scholar
  • 24 Borries M, Söhngen D, Englisch C, Schoebel FC, Stein D, Fischer Y, Boogen C, Strauer BE, Leschke M. Platelet activation in patients with coronary artery disease before and after PTCA an aspirin medication. Ann Haematol 1997; 74: 73 Abstract.
    CrossrefPubMedGoogle Scholar
  • 25 Zimmerman M, Ittner KP, Grobecker H, Alban S. Do subcutaneously applied unfractionated heparin and low molecular weight heparins influence platelet function assessed by PFA-100™?. Ann Haematol 1998; 76: 255 Abstract.
    PubMedGoogle Scholar
  • 26 Cardinal DC, Flower RJ. The electronic aggregometer : a novel device of assessing platelet behavior in blood. J Pharmacol Meth 1980; 03: 1350-8.
    PubMedGoogle Scholar
  • 27 Coller BS. Monitoring platelet GPIIb/IIIa antagonist therapy. Circulation 1998; 97: 5-9.
    CrossrefPubMedGoogle Scholar
  • 28 Casterella PJ, Kereiakes DJ, Steinhubl SR, Raymond RE, Topol EJ, Patel K, Mueller M, Rosenthal M, Teirstein PS. Use of the rapid functon analyzer (RPFA) to evaluate platelet function in patients receiving incremental bolus dosing of abciximab (ReoPro™) during percutaneous coronary interventions (PCI). J Am Coll Cardiol 1999; 33 sup: 39A. Abstract.
    CrossrefPubMedGoogle Scholar
  • 29 Theroux P, Gosselin G, Nasmith J, Cox D, Fitzgerald D, Burns D, Anders R. The Accumetrics rapid function analyzer (RPFA™) to monitor platelet aggregation during oral administration of a GPIIb/IIIa antagonist. J Am Coll Cardiol 1999; 33 sup: 330A. Abstract.
    PubMedGoogle Scholar
  • 30 Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, Koppensteiner R, Ergun E, Mittlboeck M, Schreiner W, Losert U, Wolner E. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Tschoepe D, Schultheiss HP, Kolarov P, Schwippert B, Dannehl K, Volksw D, Nieuwenhuis HK, Kehrel B, Strauer B, Gries FA. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993; 88: 37-42.
    CrossrefPubMedGoogle Scholar
  • 32 Gawaz M, Neumann FJ, Ott I, May A, Schöming A. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 1996; 94: 279-85.
    PubMedGoogle Scholar
  • 33 Neuman FJ, Gawaz M, Ott I, May A, Mössmer G, Schöming A. Prospective evaluation of haemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol 1996; 27: 15-21.
    PubMedGoogle Scholar
  • 34 Rupprecht HJ, Darius H, Borkowski U, Voigtländer T, Nowak B, Genth S, Meyer J. Comparison of antiplatelet effects of aspirin, ticlopidin, and their combination after stent implantation. Circulation 1998; 97: 1046-52.
    CrossrefPubMedGoogle Scholar
  • 35 Vorchheimer DA, Fuster V. Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety. Circulation 1998; 97: 312-14.
    CrossrefPubMedGoogle Scholar